Open-label Safety and Efficacy Evaluation of Fx-1006a in Patients with V122i Or Wild-type
Transthyretin (ttr) Amyloid Cardiomyopathy.
Patients who successfully complete Fx1B-201 will report to the clinical unit on Day 0 to sign
the informed consent form and determine eligibility for Protocol Fx1B-303. In addition, on
Day 0, patients will have their entrance criteria reviewed, and medical histories and
demographic characteristics obtained.
The physical examination (including weight and vital signs) and the relevant end of study
clinical laboratory tests (alkaline phosphatase, alanine aminotransferase, aspartate
aminotransferase, blood urea nitrogen, gamma glutamyl transferase, creatinine, total
bilirubin, international normalized ratio, troponin I, troponin T, and amino-terminal B-type
natriuretic peptide) from Protocol Fx1B-201 will be used for Protocol Fx1B-303. If more than
30 days has elapsed between the final study visit of Protocol Fx1B-201 and Day 0 of Protocol
Fx1B-303, an abbreviated physical examination (including weight and vital signs) and clinical
laboratory assessments must be performed on Day 0.
Eligible patients will begin once-daily dosing with 20 mg Fx-1006A at home on Day 1 (i.e.,
first dose) and will return to the clinical unit for study visits every 6 months.
Adverse events (AEs) and concomitant medication use will be collected at each 6-month visit
to the clinical unit. Blood draws for clinical safety laboratory tests and abbreviated
physical examinations (including weight and vital signs) will also be performed at each
6-month clinic visit. ECGs will be performed every 12 months on an annual basis. A telephone
call will be made at 3-month intervals between clinic visits to assess safety and use of
For the evaluation of efficacy, the Patient Global Assessment, NYHA classification, KCCQ,
6-minute walk test, and efficacy-related clinical laboratory tests (serum levels of troponin
T, troponin I, and NT-pro-BNP) will be determined every 6 months. In addition,
echocardiograms will be performed every 12 months on an annual basis.
An end of study visit including all safety and efficacy assessments will occur upon patient
completion of the study, premature withdrawal (for any reason), or in the event of program
discontinuation by the Sponsor.